Nvidia rebounds after Foxconn posts massive sales growth in January, highlights increasing demand for AI racks

Nvidia is rebounding from its worst five-session decline since April this morning after Hon Hai Technology Group posted massive sales growth for January, up 35.5% year on year.

Hon Hai, more commonly known as Foxconn, indicated that its cloud and networking products division (which includes servers for data centers) was its top source of sales growth.

“Shipments of AI racks continue to increase,” the electronics manufacturer said. “The seasonal performance for the current quarter is expected to be better than the range of the past five years.”

Near the start of 2026, Micron soared after Hon Hai announced better-than-expected Q4 sales.

More Markets

See all Markets

Matt Phillips6m

Memory chip makers down on chatter of customers turning to China for supplies

High-flying memory chip stocks like Sandisk and Micron are sliding Thursday after Nikkei reported some PC makers are considering turning to Chinese companies — such as ChangXin Memory Technologies — for supplies amid a historic price spike for these crucial inputs for tech devices.

HP, Dell, Acer and Asus mull using Chinese memory chips amid supply crunch, Nikkei Asia reports

Sherwood Staff

15m

We have the futures market — and Ray Dalio — to thank for the Chicken McNugget

Bridgewater founder Ray Dalio reimagined the chicken as an entity that consumes corn and soybeans on its way to being consumed by you.

Dozens Gather To Watch McDonald's Fan Eat Chicken Nuggets

Max Knoblauch17m

Nio projects its first quarterly profit, sending shares surging

Chinese EV maker Nio on Thursday said it expects to achieve its first-ever quarterly profit in its fourth quarter. Its US-traded ADRs rose more than 6% in premarket trading.

Based on a preliminary assessment, Nio projects Q4 adjusted profit from operations of between $100 million and $172 million. Wall Street analysts polled by FactSet estimated a Q4 adjusted operating loss of $19 million.

Nio attributed the preliminary results to sustained sales volume growth, vehicle margin optimization, and cost reductions. Nio delivered 124,807 vehicles in its fourth quarter, which ended in December, up 72% year over year.

J. Edward Moreno1h

Hims to offer copies of Novo’s Wegovy pill at $49 a month for starting dose

Hims & Hers will offer copies of Novo Nordisk’s Wegovy pill at $49 for a starting dose, the company announced Thursday, a sign that the company is doubling down on copycat versions of drugs over forging partnerships with Big Pharma.

Hims’ offering is $100 less than the initial price consumers would pay if buying directly from Novo. For a five-month subscription, patients pay $49 for the first month’s starting dose, then $99 per month, versus the $199 Novo charges.

The news was first reported by Reuters.

Hims rose more than 10% in premarket trading. Novo, which has already fallen about 20% since giving a gloomy sales guidance on Tuesday, fell in early trading.

The announcement comes after the two companies had an epic falling-out last year.

In June, Novo abruptly ended its short-lived deal to offer its weight-loss shot on Hims and accused the company of “illegal mass compounding and deceptive marketing.” The drugmaker reportedly expected it to stop selling copycat versions if it were to carry the FDA-approved, brand-name product.

J. Edward Moreno3h

Cigna Q4 results beat Wall Street estimates; 2026 guidance underwhelms

Cigna reported earnings results that beat Wall Street estimates in Q4, but delivered underwhelming guidance for the year ahead.

For the last three months of 2025, Cigna reported:

Adjusted earnings per share of $8.08, compared to the $7.88 analysts polled by FactSet were expecting.
Revenue of $72.4 billion, compared to the $70.3 billion the Street was penciling in.

For the full year in 2026, Cigna expects:

Annual adjusted earnings per share of at least $30.25, compared to the $30.30 analysts were expecting.
Annual revenues of about $280 billion, compared to the $285.8 billion analysts had penciled in.
Its medical cost ratio to sit between 83.7% and 84.7%, where analysts had expected 83.9%.

Health insurers have been under pressure for the past year amid rising health costs, though Cigna has been outperforming its peers.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.